摘要
射频电磁领域的投入(含)在神经退行性疾病,特别是阿尔茨海默病(AD),已经获得了广泛的关注,然而,从一些研究结果并没有表现出一致性。在这项研究中,我们确定是否影响使用含AD的病理tg-5xfad小鼠作为阿尔茨海默病淀粉样β模型体内(-β)病理学。转基因(TG)-5XFAD和野生型(WT)小鼠长期暴露于含8个月(1950兆赫,SAR 5W/kg,2小时/天,5天/周)。值得注意的是,慢性rfemf暴露显著降低不仅β斑块、APP、APP羧基末端片段(CTF)在全脑包括海马和内嗅皮质也是β42和β40肽在tg-5xfad小鼠海马的比例。我们还发现,射频电磁场暴露在tg-5xfad抑制了β-淀粉样前体蛋白裂解酶1(BACE1)的薄壁组织的表达和神经炎症反应。此外,还能减缓tg-5xfad记忆障碍。此外,利用海马WT和TG 5XFAD以下含曝光显示5基因芯片数据的基因表达谱(tshz2、gm12695、st3gal1、ISX和TLL1),这些与Aβ有关,明显改变Tg-5xfad小鼠,在WT小鼠或tg-5xfad含野生型小鼠暴露中表现出不同的反应;类似的模式来控制tg-5xfad小鼠。然而,在TG RF-EMF暴露5XFAD小鼠表现出相反的表达模式。这些结果表明,长期暴露在含直接影响阿尔茨海默病病理Aβ但在正常的大脑。因此,含对阿尔茨海默病样Aβ高表达在晚期阿尔茨海默病小鼠的病理预防作用,这表明RF-EMF对阿尔茨海默氏病有好的影响。
关键词: 阿尔茨海默病小鼠,β-淀粉样蛋白,β-淀粉样前体蛋白裂解酶1,基因芯片,射频电磁场
Current Alzheimer Research
Title:1950 MHz Electromagnetic Fields Ameliorate Aβ Pathology in Alzheimer’s Disease Mice
Volume: 12 Issue: 5
Author(s): Ye Ji Jeong, Ga-Young Kang, Jong Hwa Kwon, Hyung-Do Choi, Jeong-Ki Pack, Nam Kim, Yun-Sil Lee and Hae-June Lee
Affiliation:
关键词: 阿尔茨海默病小鼠,β-淀粉样蛋白,β-淀粉样前体蛋白裂解酶1,基因芯片,射频电磁场
摘要: The involvement of radiofrequency electromagnetic fields (RF-EMF) in the neurodegenerative disease, especially Alzheimer’s disease (AD), has received wide consideration, however, outcomes from several researches have not shown consistency. In this study, we determined whether RF-EMF influenced AD pathology in vivo using Tg-5xFAD mice as a model of AD-like amyloid β (Aβ) pathology. The transgenic (Tg)-5xFAD and wild type (WT) mice were chronically exposed to RF-EMF for 8 months (1950 MHz, SAR 5W/kg, 2 hrs/day, 5 days/week). Notably, chronic RFEMF exposure significantly reduced not only Aβ plaques, APP, and APP carboxyl-terminal fragments (CTFs) in whole brain including hippocampus and entorhinal cortex but also the ratio of Aβ42 and Aβ40 peptide in the hippocampus of Tg-5xFAD mice. We also found that parenchymal expression of β-amyloid precursor protein cleaving enzyme 1(BACE1) and neuroinflammation were inhibited by RF-EMF exposure in Tg-5xFAD. In addition, RF-EMF was shown to rescue memory impairment in Tg-5xFAD. Moreover, gene profiling from microarray data using hippocampus of WT and Tg- 5xFAD following RF-EMF exposure revealed that 5 genes (Tshz2, Gm12695, St3gal1, Isx and Tll1), which are involved in Aβ, are significantly altered inTg-5xFAD mice, exhibiting different responses to RF-EMF in WT or Tg-5xFAD mice; RF-EMF exposure in WT mice showed similar patterns to control Tg-5xFAD mice, however, RF-EMF exposure in Tg- 5xFAD mice showed opposite expression patterns. These findings indicate that chronic RF-EMF exposure directly affects Aβ pathology in AD but not in normal brain. Therefore, RF-EMF has preventive effects against AD-like pathology in advanced AD mice with a high expression of Aβ, which suggests that RF-EMF can have a beneficial influence on AD.
Export Options
About this article
Cite this article as:
Ye Ji Jeong, Ga-Young Kang, Jong Hwa Kwon, Hyung-Do Choi, Jeong-Ki Pack, Nam Kim, Yun-Sil Lee and Hae-June Lee , 1950 MHz Electromagnetic Fields Ameliorate Aβ Pathology in Alzheimer’s Disease Mice, Current Alzheimer Research 2015; 12 (5) . https://dx.doi.org/10.2174/156720501205150526114448
DOI https://dx.doi.org/10.2174/156720501205150526114448 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Key Role of Mitochondria in Alzheimer’s Disease Synaptic Dysfunction
Current Pharmaceutical Design Recent Approaches Targeting Beta-Amyloid for Therapeutic Intervention of Alzheimer's disease
Recent Patents on CNS Drug Discovery (Discontinued) IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Current Drug Targets Age-Related Sleep Changes and its Implication in Neurodegenerative Diseases
Current Aging Science Adult Neurogenesis: Can Analysis of Cell Cycle Proteins Move Us “Beyond BrdU”?
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member:
Current Alzheimer Research Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Current Psychopharmacology A Hyperlipidemic Diet Induces Structural Changes in Cerebral Blood Vessels
Current Neurovascular Research Hydroxamate, a Key Pharmacophore Exhibiting a Wide Range of Biological Activities
Mini-Reviews in Medicinal Chemistry Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Autosomal Recessive Hereditary Spastic Paraplegia: A Rare Case of a Family with Phenotypic Variation
Current Pharmacogenomics and Personalized Medicine Editorial [Hot Topic: Protease Inhibitors in Drug Discovery (Guest Editor: Francis X. Tavares)]
Current Topics in Medicinal Chemistry Preface
Current Topics in Medicinal Chemistry Molecule of the Month
Current Topics in Medicinal Chemistry Is Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?
Current Neuropharmacology Recent Progresses in Application of Fullerenes in Cosmetics
Recent Patents on Biotechnology Editorial - Progress and Vision for ‘Current Aging Science’
Current Aging Science Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease
Current Topics in Medicinal Chemistry Endogenous Regulators of Adult CNS Neurogenesis
Current Pharmaceutical Design Discovery of Novel CK2 Leads by Cross-Docking Based Virtual Screening
Medicinal Chemistry